Clinical efficacy of Aidi Injection combined with conventional chemotherapy in patients with lung cancer brain metastasis
Objective To observe the clinical application of Aidi Injection combined with conventional chemotherapy in patients with lung cancer brain metastases.Methods A retrospective analysis was conducted on the clinical data of 80 patients with lung cancer brain metastasis who visited the Lishui People's Hospital from June 2018 to June 2020.They were divided into conventional chemotherapy group and Aidi group based different treatment methods.Patients in the conventional chemotherapy group received chemotherapy with cisplatin com-bined with docetaxel,while patients in the Aidi group received Aidi Injection in addition to conventional chemotherapy.The short-term efficacy,cognitive function,and adverse reactions between the two groups were compared,and the effectiveness and safety of this combination therapy approach were evaluated.Results Com-pared with the conventional chemotherapy group,the short-term effective rate of patients in the Aidi group was higher(x2=4.266,P=0.039),50％for the conventional chemotherapy group,and 73％for the Aidi group.Before the treatment initiation,there was no statistically significant difference in the MoCA scores and MMSE scores between the two groups.After 2 weeks of treatment,compared with the conventional chemotherapy group,the MoCA and MMSE scores in the Aidi group were significantly increased(t=-3.462,-2.507;P=0.001,0.047);and the Karnof-sky scores and QOL scores in the Aidi group were also significantly increased(t=-4.634,-4.050;P＜0.01).Com-pared with the conventional chemotherapy group,patients in the Aidi group showed a significant reduction in bone marrow suppression and dizziness(x2=4.126,4.050;P=0.042,0.044),while gastrointestinal reactions such as nausea and vomiting and hair loss had been alleviated,but the difference was not statistically significant(P＞0.05).All 80 patients mentioned above ultimately died due to this disease.The median survival period for the con-ventional chemotherapy group was(15±3)months,while it was(18±4)months for the Aidi group.The difference between the two groups was not statistically significant(x2=17.752,P＜0.01).Conclusion Combining Aidi Injec-tion with conventional chemotherapy regimens for treating lung cancer brain metastases can enhance short-term efficacy,alleviate cognitive impairments,and reduce the toxic side effects of chemotherapy.However,it does not have a significant impact on patients'survival periods.
Ai Di Zhu She YeChemotherapyLung neoplasmsBrain metastasisCognitive functionClinical efficacy
万方数据
维普
